Prothena Corporation plc (LON:0Y3M)

Market Cap	317.58M
Revenue (ttm)	7.55M
Net Income (ttm)	-221.10M
Shares Out	n/a
EPS (ttm)	-4.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	198
Average Volume	5,034
Open	8.49
Previous Close	8.24
Day's Range	8.49 - 8.49
52-Week Range	4.34 - 22.55
Beta	-0.04
RSI	54.40
Earnings Date	Nov 6, 2025

About Prothena Corporation

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson’s disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potent...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 163
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0Y3M

Financial Performance

In 2024, Prothena Corporation's revenue was $135.16 million, an increase of 47.92% compared to the previous year's $91.37 million. Losses were -$122.31 million, -16.81% less than in 2023.

Financial numbers in USD